Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Illinois: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 38 | 2,104 | 30% |
| 2020 | 26 | 2,000 | 33% |
| 2021 | 29 | 2,241 | 37% |
| 2022 | 25 | 2,159 | 42% |
| 2023 | 27 | 2,192 | 45% |
| 2024 | 28 | 2,235 | 47% |
| 2025 from claims | – | 2,480 2,276–2,624 | 48% |
| 2026 forecast | – | 2,599 2,287–3,000 | 48% |
| 2027 forecast | – | 2,701 2,309–3,218 | 48% |
| 2028 forecast | – | 2,806 2,341–3,435 | 49% |
| 2029 forecast | – | 2,914 2,380–3,655 | 50% |
| 2030 forecast | – | 3,027 2,425–3,879 | 50% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 55% of the cases CMS names in Illinois; 19 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 74% inpatient hospital, 8% hospital outpatient, 6% surgery center, 12% office. The share outside the hospital has moved +14 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Michigan | 10 | 1,534−1.8%/yr | −1.8%/yr | 1.8 | 18% | 1,770 in 2030+2.4%/yr |
| Ohio | 6 | 1,351−4.1%/yr | −4.1%/yr | 1.2 | 0% | 1,470 in 2030+1.4%/yr |
| Indiana | 7 | 1,264+6.5%/yr | +6.5%/yr | 1.8 | 15% | 1,940 in 2030+7.4%/yr |
| Missouri | 8 | 855−5.5%/yr | −5.5%/yr | 1.4 | 0% | 790 in 2030−1.3%/yr |
| Wisconsin | 1 | 601−4.2%/yr | −4.2%/yr | 1.1 | 5% | 1,010 in 2030+9.1%/yr |
| Minnesota | 3 | 534−2.8%/yr | −2.8%/yr | 1.2 | 0% | 1,150 in 2030+14%/yr |
| Kansas | 2 | 454+4.3%/yr | +4.3%/yr | 1.1 | 0% | 920 in 2030+12%/yr |
| South Dakota | 6 | 318+3.2%/yr | +3.2%/yr | 2.5 | 0% | 220 in 2030−5.7%/yr |
| Iowa | 1 | 3090%/yr | 0%/yr | 0.7 | 0% | 490 in 2030+8.2%/yr |
| Nebraska | 1 | 272−1.9%/yr | −1.9%/yr | 1.1 | 0% | 220 in 2030−3.7%/yr |
| North Dakota | 1 | 126−1.2%/yr | −1.2%/yr | 1.3 | 0% | 260 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 97 | 8,273−2.9%/yr | −2.9%/yr | 5.82.0× | 94% | 9,750 in 2030+2.8%/yr |
| Dialysis access | 87 | 7,931−11%/yr | −11%/yr | 5.91.4× | 73% | 7,380 in 2030−1.2%/yr |
| Peripheral arterial intervention | 47 | 6,194−7.5%/yr | −7.5%/yr | 4.31.0× | 41% | 6,330 in 2030+0.4%/yr |
| Carotid revascularization | 31 | 1,439−3.9%/yr | −3.9%/yr | 1.00.9× | 0% | 1,600 in 2030+1.8%/yr |
| Aortic endografts (EVAR/TEVAR) | 7 | 563−7.4%/yr | −7.4%/yr | 0.40.8× | 0% | 600 in 2030+1.1%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Illinois · Every state · Compare with Michigan
Stryker leads with 48% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 15 companies reported engagement with Illinois’s surgeons worth $443K in consulting, speaking, meals and travel tied to these products, about $16K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.